Effects of Liraglutide as Add-on to Metformin on Hepatic Steatosis and Fibrosis in Patients with Prediabetes and MASLD: A Retrospective Cohort Study
Background and Aims: The coexistence of prediabetes and metabolic dysfunction-associated steatotic liver disease (MASLD) is common and accelerates metabolic and hepatic complications. This study evaluated the effects of liraglutide on hepatic steatosis and fibrosis in patients with prediabetes and MASLD. Methods: This retrospective cohort study included 263 patients with prediabetes and MASLD who received either liraglutide plus metformin (liraglutide group, n=142) or metformin alone (control group, n=121) for 12 months. Primary outcomes were changes in controlled attenuation parameter (CAP), liver stiffness measurement (LSM), Fibrosis-4 (FIB-4) index, and non-alcoholic fatty liver disease fibrosis score (NFS). Secondary outcomes included anthropometric measurements, glycemic parameters, lipid profiles, and liver enzymes. Results: After 12 months of treatment, CAP values decreased significantly in both groups (both p<0.001), with significantly lower values in the liraglutide group compared to the control group (p<0.001). LSM showed significant reductions in both groups, with more pronounced improvement in the liraglutide group (p<0.001) and significantly lower values compared to the control group at 12 months (p<0.05). FIB-4 index and NFS decreased significantly in both groups (p<0.05), though between-group differences did not reach statistical significance (p>0.05). The liraglutide group achieved significantly greater improvements in body weight, waist circumference, glycemic parameters [fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR)], triglycerides, and non-high-density lipoprotein (HDL) cholesterol compared to the control group (all p<0.05). Liver enzymes [alanine aminotransferase (ALT), aspartate aminotransferase (AST]), gamma-glutamyl transferase (GGT)] improved significantly in both groups, with greater reductions in the liraglutide group (all p<0.001). The most common adverse events were mild-to-moderate gastrointestinal symptoms, with no serious adverse events reported. Conclusions: In patients with prediabetes and MASLD, 12-month liraglutide as add-on therapy to metformin was associated with significant improvements in hepatic steatosis and liver stiffness measurement compared to metformin monotherapy, alongside favorable metabolic effects and an acceptable safety profile. These findings support liraglutide as a potential therapeutic option for this high-risk population.
Authors
- Renmin Tang
- Qin He (ORCID: https://orcid.org/0009-0009-1126-6940)
- Jianming Yang (ORCID: https://orcid.org/0009-0008-6876-4193)
- Wen Wang
Institutions
- Yichang Central People's Hospital (CN)
Publication Details
- Journal
- Journal of Gastrointestinal and Liver Diseases
- Published
- 2026-11-21
- DOI
- https://doi.org/10.15403/jgld-6926
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00